Seviteronel Clinical Development StudiesÂ
Seviteronel is in Phase 2 clinical development for both breast and prostate cancer. Patients are joining the studies at clinics and major medical centers across the United States. If you, a loved one, or someone you know are interested in participating in one of the studies described below, and would like more information, please contact Lisa Franklin at: 919-695-9493.
Breast Cancer Clinical Studies
Study 006: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of INO-464 in Patients With Advanced Breast Cancer
Currently enrolling men with breast cancer and women with triple-negative breast cancer.
Prostate Cancer Clinical Studies
Study 001: A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INO-464 in Patients with Castration-Resistant Prostate Cancer.
Currently enrolling men with castration-resistant prostate cancer who were previously treated with abiraterone or enzalutamide.
Study 002: A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of INO-464 in Patients with Metastatic Castration Resistant Prostrate Cancer Who Have Previously Been Treated With Enzalutamide
Currently enrolling men with castration-resistant prostate cancer who were previously treated with enzalutamide.
Study 003: A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Once-Daily Oral INO-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Currently enrolling men with castration-resistant prostate cancer who were previously treated with abiraterone or enzalutamide.
Study 004: A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Once-Daily INO-464 in Patients with Castration-Resistant Prostate Cancer.
Enrollment for the study is complete.
Â